Earendil: A Blueprint for a Multipolar Life Sciences Era
-
By
-
Joe Renny
-
June 5, 2026
-
5 min
By
Joe Renny
June 5, 2026
Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.
June 5, 2026